The problem of the use of hormonal therapy aimed for sex correction by transgender persons on their own initiative

BACKGROUND: In recent years, the demand for feminizing and masculinizing hormone therapy has increased significantly among transgender people around the world. There are no such studies in Russia and the amount of medical information on the transgender population is limited.

AIM: to assess the number of transgender patients who take hormone therapy without a doctor’s prescription and to characterize the medicines they use.

MATERIALS AND METHODS: data from 1117 transgender patients were included in to analysis: 44.01% (n=515) of them were trans women, 55.99% (n=630) were trans men. Patients applied to the “Scientific Center for Personalized Medicine” in order to receive medical care.

RESULTS: Half of transgender people (53.6%) are already taking hormonal drugs. More often transgender women (76.7%), less often transgender men (32.3%). In this case, only 8.6% turned to endocrinologists for the therapy prescription. Many patients used unlicensed drugs, use irrational schemes and combinations, often overdose.

CONCLUSION: A significant number of transgender people start using hormone replacement therapy on their own initiative, without the doctor’s supervision. The solution to this problem could be incensement of knowledge level in doctors and patients to create a friendly environment and productive interaction between therapists, endocrinologists and transgender people, as well as the organization of consulting centers within public medical institutions.

1. Nolan IT, Kuhner CJ, Dy GW. Demographic and temporal trends in transgender identities and gender confirming surgery. Transl Androl Urol. 2019;8(3):184-190. doi: https://doi.org/10.21037/tau.2019.04.09

2. Sоlov’eva NV, Makarova EV, Vil’yanov VB, et al. Socio-demographic portrait of transsexual patients in Russia. Medical Council. 2019;6:148-153. (In Russ.)]. doi: https://doi.org/10.21518/2079-701X-2019-6-148-153

3. Meerwijk EL, Sevelius JM. Transgender Population Size in the United States: A Meta-Regression of Population-Based Probability Samples. Am. J. Public Health. 2017;107:e1-e8. doi: https://doi.org/10.2105/AJPH.2016.303578

4. The Gender Identity Research and Education Society [Internet]. [cited: 13 May 2018)]; Available from: http://www.gires.org.uk/wp-content/uploads/2014/10/Prevalence2011.pdf

5. Standards of Care for the Health of Transsexual,Transgender, and Gender-Nonconforming People, Version 7. World Professional Association for Transgender Health, 2018. 260 p. (In Russ.).

6. Tanis J. The power of 41%: A glimpse into the life of a statistic. American Journal of Orthopsychiatry. 2016;86(4):373-377. doi: https://doi.org/10.1037/ort0000200

7. Beek TF, Cohen-Kettenis PT, Kreukels BP. Gender incongruence/gender dysphoria and its classification history. Int Rev Psychiatry. 2016;28(1):5-12. doi: https://doi.org/10.3109/09540261.2015.1091293

8. Rotondi NK, Bauer GR, Scanlon K, et al. Nonprescribed hormone use and self-performed surgeries: «do-it-yourself» transitions in transgender communities in Ontario, Canada. Am J Public Health. 2013;103(10):1830-1836. doi: https://doi.org/10.2105/AJPH.2013.301348

9. Order of the Ministry of Health of the Russian Federation of October 23, 2017 No. 850n «On approval of the form and procedure for issuing a document on gender reassignment by a medical organization» (In Russ.).

10. Mepham N, Bouman WP, Arcelus J, et al. People with gender dysphoria who self-prescribe cross-sex hormones: prevalence, sources, and side effects knowledge. J Sex Med. 2014;11(12):2995-3001. doi: https://doi.org/10.1111/jsm.12691

11. Shatzel JJ, Connelly KJ, DeLoughery TG. Thrombotic issues in transgender medicine: A review. Am J Hematol. 2017;92(2):204-208. doi: https://doi.org/10.1002/ajh.24593

12. Unger CA. Hormone therapy for transgender patients. Transl Androl Urol. 2016;5(6):877-884. doi: https://doi.org/10.21037/tau.2016.09.04

13. Dekker MJ, Wierckx K, Van Caenegem E, et al. A European Network for the Investigation of Gender Incongruence: Endocrine Part. J Sex Med. 2016;13(6):994-999. doi: https://doi.org/10.1016/j.jsxm.2016.03.371

14. Wierckx K, Mueller S, Weyers S, et al. Long-term evaluation of cross-sex hormone treatment in transsexual persons. J Sex Med. 2012;9(10):2641-2651. doi: https://doi.org/10.1111/j.1743-6109.2012.02876.x

15. Wierckx K, Van Caenegem E, Schreiner T, et al. Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European network for the investigation of gender incongruence. J Sex Med. 2014;11(8):1999-2011. doi: https://doi.org/10.1111/jsm.12571

16. Nolan BJ, Cheung AS. Relationship Between Serum Estradiol Concentrations and Clinical Outcomes in Transgender Individuals Undergoing Feminizing Hormone Therapy: A Narrative Review. Transgend Health. 2021;6(3):125-131. doi: https://doi.org/10.1089/trgh.2020.0077

17. Antun A, Zhang Q, Bhasin S, et al. Longitudinal Changes in Hematologic Parameters Among Transgender People Receiving Hormone Therapy. J Endocr Soc. 2020;4(11):bvaa119. doi: https://doi.org/10.1210/jendso/bvaa119

18. Connelly PJ, Marie Freel E, Perry C, et al. Gender-Affirming Hormone Therapy, Vascular Health and Cardiovascular Disease in Transgender Adults. Hypertension. 2019;74(6):1266-1274. doi: https://doi.org/10.1161/HYPERTENSIONAHA.119.13080

19. Shadid S, Abosi-Appeadu K, De Maertelaere AS, et al. Effects of Gender-Affirming Hormone Therapy on Insulin Sensitivity and Incretin Responses in Transgender People. Diabetes Care. 2020;43(2):411-417. doi: https://doi.org/10.2337/dc19-1061

20. Wierckx K, Van de Peer F, Verhaeghe E, et al. Short‐ and Long‐Term Clinical Skin Effects of Testosterone Treatment in Trans Men. J Sex Med. 2014;11(1):222-229. doi: https://doi.org/10.1111/jsm.12366

21. Xavier J. Final Report of the Washington Transgender Needs Assessment Survey. Washington, DC: Administration for HIV and AIDS, Government of the District of Columbia; 2000.

22. Xavier J, Honnold JA, Bradford J. The Health, Health-Related Needs, and Lifecourse Experiences of Transgender Virginians: Virginia Transgender Health Initiative Study Statewide Survey Report. Richmond, VA: Virginia Department of Health, Division of Disease Prevention through the Centers for Disease Control and Prevention; 2007.

23. Clements-Nolle K, Marx R, Guzman R, Katz M. HIV prevalence, risk behaviors, health care use, and mental health status of transgender persons: implications for public health intervention. Am J Public Health. 2001;91(6):915-921. doi: https://doi.org/10.2105/AJPH.91.6.915

24. Sanchez NF, Sanchez JP, Danoff A. Health Care Utilization, Barriers to Care, and Hormone Usage Among Male-to-Female Transgender Persons in New York City. Am J Public Health. 2009;99(4):713-719. doi: https://doi.org/10.2105/AJPH.2007.132035

25. Krasnov VYa, Gurevich IYa. Klinicheskoe rukovodstvo: modeli diagnostiki i lecheniya psikhicheskikh i povedencheskikh rasstroistv. Moscow: Mosk. NII psikhiatrii Minzdrava Rossii, 1999. 224 p. (In Russ.).

26. Kuijpers SME, Wiepjes CM, Conemans EB, et al. Toward a Lowest Effective Dose of Cyproterone Acetate in Trans Women: Results From the ENIGI Study. J Clin Endocrinol Metab. 2021;106(10):e3936-e3945. doi: https://doi.org/10.1210/clinem/dgab427

27. Nota NM, Dekker MJHJ, Klaver M, et al. Prolactin levels during short- and long-term cross-sex hormone treatment: an observational study in transgender persons. Andrologia. 2017;49(6):e12666. doi: https://doi.org/10.1111/and.12666

28. Paz-Otero M, Becerra-Fernández A, Pérez-López G, et al. A 2020 Review of Mental Health Comorbidity in Gender Dysphoric and Gender Non-Conforming People. J Psychiatry Treat Res. 2021;3(1):44-55. doi: https://doi.org/10.36959/784/425

29. Player M, Jones A. Compulsory Transgender Health Education: The Time Has Come. Fam Med. 2020; 52(6): 395-397. doi: https://doi.org/10.22454/FamMed.2020.647521